Abstract:In humans, dual-specificity Tyrosine-Phosphorylation-Regulated Kinase 1A is an enzyme encoded by the DYRK1A gene involved in various diseases, including DYRK1A syndrome, cancer, diabetes, and neurodegenerative pathologies such as Alzheimer’s disease (AD). AD is the most prevalent form of dementia, accounting for 60–80% of cases and remains an unmet medical challenge with no cure and just palliative treatments. Recent studies have identified DYRK1A as a promising therapeutic target in AD, given its involvement in multiple biological functions and its alterations correlated with AD progression. In this work, we leverage multiple Artificial Intelligence (AI) tools, including pre- dictive models and generative algorithms, to design non-toxic DYRK1A inhibitors. We construct a dual-target drug discovery framework integrating AI-driven meth- ods with classical techniques to identify novel compounds. An ensemble Quanti- tative Structure-Activity Relationship (QSAR) model is employed for predicting compound affinities, while Directed Message Passing Neural Networks (DMPNN) are used to assess toxicity. In a generative phase, a Hierarchical Graph Genera- tion model (HGG) facilitated the design of potential DYRK1A inhibitors. Promis- ing candidate molecules were refined through classical docking studies, leading to their synthesis and experimental validation. As a result, pyrazolyl-1H -pyrrolo[2,3- b]pyridine was identified as a potent DYRK1A inhibitor, leading to the synthesis of a new derivative series. Enzymatic assays demonstrated nanomolar-level inhibitory activity, while anti-inflammatory and antioxidant properties were confirmed through ORAC assays and LPS-induced pro-inflammatory response evaluations in BV2 mi- croglial cells. Pharmacological testing revealed that the mentioned compound and its derivatives exhibit significant DYRK1A inhibition alongside robust antioxidant and anti-inflammatory effects.

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation

DYRK1A inhibitors for disease therapy: Current status and perspectives

Recent research and development of DYRK1A inhibitors

Selective Macrocyclic Inhibitors of DYRK1A/B.

A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD)

Discovery of a novel DYRK1A inhibitor with neuroprotective activity by virtual screening and in vitro biological evaluation

Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease

Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A

Insights into Mechanism of Pyrido[2,3-D]pyrimidines As DYRK1A Inhibitors Based on Molecular Dynamic Simulations.

AI-driven de-novo design and development of non-toxic DYRK1A inhibitors for Alzheimer’s disease

Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry

Discovery of a Novel Chemotype As DYRK1A Inhibitors Against Alzheimer’s Disease: Computational Modeling and Biological Evaluation

DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis

Structural perspective on the design of selective DYRK1B inhibitors

Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes

Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer's Disease and Down Syndrome

Disruption of DYRK1A-induced hyperphosphorylation of amyloid-beta and tau protein in Alzheimer's disease: An integrative molecular modeling approach

Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases

Selective inhibition of the kinase DYRK1A by targeting its folding process

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B